Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 to 75 Women only

Hypofractionated radiotherapy after prosthetic breast reconstruction

Official title: Randomized Controlled Trial of Postmastectomy Hypofractionated Radiotherapy Versus Conventional Fractionated Radiotherapy in Breast Cancer Patients Undergoing Prosthetic Breast Reconstruction

Run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT07084519 · Data updated 2026-11-12

This study tests whether a shorter, higher-dose radiotherapy course (HFRT) works as safely and effectively as the standard longer course (CFRT) for patients who had a mastectomy with implant reconstruction.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 75 Years
SexWomen only
Enrollment506 (estimated)
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Beijing, Province)
StatusRecruiting
StartedMarch 27, 2026
Main results expectedMarch 27, 2029
Study endsDecember 31, 2030
Registry record updatedJune 22, 2026
Trial IDNCT07084519 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18-75 with high-risk invasive breast cancer after mastectomy and immediate implant-based reconstruction, adequate performance status, no distant metastasis, and completion of standard chemotherapy.

Probably not a fit

Patients with prior chest wall radiotherapy, certain advanced disease features, bilateral reconstruction needing radiotherapy, or specific implant-related complications may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3 interventional trial comparing hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) in women with high-risk breast cancer who have undergone total mastectomy with immediate prosthetic reconstruction. Participants are randomized to receive HFRT: 43.5 Gy in 15 fractions over three weeks, or CFRT: 50 Gy in 25 fractions over five weeks. The primary endpoint is the reconstruction failure rate, including implant removal and capsular contracture. Eligible patients are adults with good performance status who completed standard chemotherapy and meet specific tumor and surgical criteria, with no distant metastasis or prior chest wall radiotherapy. The study is conducted at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, in Beijing.

Why it matters

Potential benefit: If HFRT is as safe and effective as CFRT, patients may receive the same cancer control with a shorter treatment time and potentially fewer clinic visits.

How similar studies have gone: Prior radiotherapy studies in breast cancer have shown hypofractionation can be effective; this trial applies HFRT specifically to post-mmastectomy reconstruction scenarios, which is less established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female, aged 18-75 years
* Karnofsky Performance Status ≥60
* Histopathologically confirmed invasive breast adenocarcinoma
* Total mastectomy \[with or without nipple-areolar complex preservation\] + axillary dissection/sentinel lymph node biopsy + implant/expander placement R0 resection with negative margins
* pT3 or N2-3 disease; or pT1-2N1
* No distant metastasis
* Completed standard neoadjuvant/adjuvant chemotherapy cycles
* ≤8 weeks post-chemotherapy or ≤12 weeks post-surgery if no chemotherapy
* Signed informed consent

Exclusion Criteria:

* Prior radiotherapy to chest wall or nodal regions
* Pregnancy or lactation
* T4 stage disease
* Autologous breast reconstruction of the irradiated breast
* Pre-radiotherapy local/regional/distant metastasis
* Grade ≥3 implant-related adverse events irreversible before radiotherapy
* Bilateral breast cancer requiring bilateral radiotherapy
* Concurrent/secondary malignancy with disease-free interval \<5 years \[except non-melanoma skin cancer, papillary/follicular thyroid cancer, or cervical carcinoma in situ\]
* Active collagen vascular disease, e.g., SLE, scleroderma
* Uncontrolled comorbidities: acute cardiovascular disease, substance abuse, or psychiatric disorders

Where it's running

  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, Province, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.